Talaris Therapeutics Price To Book vs. Book Value Per Share

TALSDelisted Stock  USD 2.98  0.10  3.25%   
Based on Talaris Therapeutics' profitability indicators, Talaris Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Talaris Therapeutics' ability to earn profits and add value for shareholders.
For Talaris Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Talaris Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Talaris Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Talaris Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Talaris Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Please note, there is a significant difference between Talaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Talaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Talaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Talaris Therapeutics Book Value Per Share vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Talaris Therapeutics's current stock value. Our valuation model uses many indicators to compare Talaris Therapeutics value to that of its competitors to determine the firm's financial worth.
Talaris Therapeutics is currently regarded as top stock in price to book category among its peers. It also is currently regarded as top stock in book value per share category among its peers creating about  12.63  of Book Value Per Share per Price To Book. Comparative valuation analysis is a catch-all technique that is used if you cannot value Talaris Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Talaris Book Value Per Share vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Talaris Therapeutics

P/B

 = 

MV Per Share

BV Per Share

 = 
0.28 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Talaris Therapeutics

Book Value per Share

 = 

Common Equity

Average Shares

 = 
3.49 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Talaris Book Value Per Share Comparison

Talaris Therapeutics is currently under evaluation in book value per share category among its peers.

Talaris Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Talaris Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Talaris Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Talaris Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Talaris Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky. Talaris Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 128 people.

Talaris Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Talaris Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Talaris Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Talaris Therapeutics' important profitability drivers and their relationship over time.

Use Talaris Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Talaris Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Talaris Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Talaris Therapeutics Pair Trading

Talaris Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Talaris Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Talaris Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Talaris Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Talaris Therapeutics to buy it.
The correlation of Talaris Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Talaris Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Talaris Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Talaris Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Talaris Therapeutics position

In addition to having Talaris Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Macroaxis Index Thematic Idea Now

Macroaxis Index
Macroaxis Index Theme
An experimental equal-weighted index theme of selected equities generated based on Macroaxis rating and scoring system. The Macroaxis Index theme has 52 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Index Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Consideration for investing in Talaris Stock

If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA